PSD2 (Phosphatidylserine Decarboxylase), also known as phosphatidylserine decarboxylase, is a crucial enzyme in phospholipid metabolism. PSD2 catalyzes the decarboxylation of phosphatidylserine to generate phosphatidylethanolamine, a critical component of cellular membranes. This enzyme is essential for maintaining membrane lipid homeostasis, particularly in neuronal cells where phospholipid composition is critical for synaptic function, neuronal viability, and cellular signaling. Dysregulation of PSD2 and phospholipid metabolism has been implicated in various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. [@vance1990, @kuge1995]
| Property | Value |
|---|---|
| Gene Symbol | PSD2 |
| Gene Name | Phosphatidylserine Decarboxylase |
| Aliases | PSD2, PSS1, PTDSS1 |
| Chromosomal Location | 5q14.3 |
| NCBI Gene ID | 151742 |
| OMIM | 612596 |
| UniProt | Q8N5L0 |
| Ensembl | ENSG00000146054 |
| Protein Class | Phospholipid biosynthesis enzyme |
| Expression | Brain, liver, testis, widespread |
Note: The gene symbol PSD2 should not be confused with PSD-95 (encoded by DLG4), a major postsynaptic density scaffolding protein, despite some confusion in early literature. This page focuses on the enzyme phosphatidylserine decarboxylase.
PSD2 is a pyridoxal phosphate (PLP)-dependent enzyme that catalyzes the decarboxylation of phosphatidylserine to phosphatidylethanolamine:
Reaction: Phosphatidylserine → Phosphatidylethanolamine + CO₂
The enzymatic mechanism involves:
This reaction is unique among phospholipid biosynthesis enzymes as it directly generates phosphatidylethanolamine without requiring additional energy (e.g., ATP). [1]
PSD2 has a distinctive subcellular distribution:
The dual localization of PSD2 reflects the complex network of phospholipid metabolism in neurons, where proper distribution of phosphatidylserine and phosphatidylethanolamine is critical for synaptic function. [2]
PSD2 plays a central role in phospholipid metabolism:
Kennedy Pathway: PSD2 functions in the de novo phospholipid biosynthesis pathway (Kennedy pathway):
Lands Cycle: Phospholipid remodeling through the Lands cycle involves PSD2 products in acyl chain remodeling.
CDP-ethanolamine pathway: An alternative route to phosphatidylethanolamine involving CDP-ethanolamine.
Phosphatidylethanolamine generated by PSD2 serves as:
Phosphatidylethanolamine and phosphatidylserine are critical for neuronal membrane properties:
Membrane fluidity: Phosphatidylethanolamine promotes negative curvature and influences membrane fusion events, crucial for synaptic vesicle exocytosis and endocytosis.
Lipid rafts: The composition of lipid rafts (cholesterol-rich membrane microdomains) depends on phospholipid content, affecting receptor signaling and protein trafficking.
Synaptic vesicle function: Proper phosphatidylethanolamine content is essential for:
Myelin formation: Phospholipid composition affects oligodendrocyte function and myelin stability.
Phospholipid metabolism directly influences synaptic signaling:
Synaptic plasticity: Phospholipid composition affects long-term potentiation (LTP) and long-term depression (LTD) through:
Neurotransmitter release: Phosphatidylethanolamine content regulates:
Postsynaptic density: While PSD-95 (DLG4) is the major postsynaptic scaffold protein, phospholipid composition influences PSD organization and function. [@sheng2019, @kim2020]
Phosphatidylserine has a well-known role in apoptosis:
Apoptotic externalization: In early apoptosis, phosphatidylserine is externalized to the outer plasma membrane leaflet, serving as an "eat-me" signal for phagocytes.
Neuroprotection: Proper intracellular phosphatidylserine levels regulate:
Neurodegeneration: Altered phosphatidylserine metabolism contributes to:
Phospholipids are essential for mitochondrial health:
Mitochondrial membranes: Phosphatidylethanolamine is a major component of mitochondrial inner membrane, affecting electron transport chain function.
Mitochondrial dynamics: Phospholipid composition influences:
Bioenergetics: Impaired phospholipid metabolism affects ATP production and neuronal energy balance. [6]
PSD2 expression varies across tissues:
Within the brain:
Phospholipid metabolism is significantly altered in Alzheimer's disease:
Phosphatidylserine deficiency: Multiple studies have documented reduced phosphatidylserine levels in AD brain tissue, correlating with cognitive decline. [7]
PSD2 dysregulation: Altered PSD2 expression and activity in AD models:
Membrane dysfunction: Phospholipid alterations contribute to:
Therapeutic approaches: Phosphatidylserine supplementation has been investigated as a potential therapy for cognitive decline in AD. [8]
Phospholipid alterations in PD:
Dopaminergic neurons: Phospholipid metabolism is particularly vulnerable in dopaminergic neurons due to their high metabolic demands.
Mitochondrial dysfunction: PSD2 and phospholipid metabolism affect:
α-Synuclein interaction: Phospholipids, particularly phosphatidylserine, interact with α-synuclein and influence its aggregation.
Potential therapies: Phospholipid-targeted approaches are being explored for PD neuroprotection.
Amyotrophic Lateral Sclerosis (ALS): Altered phospholipid metabolism in motor neurons.
Huntington's Disease: Phospholipid changes affecting neuronal survival.
Multiple Sclerosis: Myelin phospholipid composition affects demyelination and remyelination.
Age-related cognitive decline: General phospholipid alterations with aging.
Liver disease: PSD2 is highly expressed in liver; hepatic dysfunction affects phospholipid homeostasis.
Cardiovascular disease: Phospholipid metabolism affects vascular function.
Cancer: Altered phospholipid metabolism in cancer cell proliferation.
One therapeutic approach involves supplementation:
Targeting PSD2 and related enzymes:
PSD2 encodes phosphatidylserine decarboxylase, a crucial enzyme in phospholipid metabolism that catalyzes the conversion of phosphatidylserine to phosphatidylethanolamine. This enzyme is essential for maintaining proper neuronal membrane composition, synaptic function, and cell survival. Phospholipid metabolism, including the PSD2-mediated pathway, is significantly altered in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. Understanding the role of PSD2 in neuronal health and disease may lead to novel therapeutic approaches targeting phospholipid homeostasis for neuroprotection.
Tavolieri et al. Phosphatidylserine in neural membranes. Progress in Lipid Research. 2014. ↩︎
Kim et al. Membrane lipid composition and neuronal function. Nature Reviews Neuroscience. 2018. ↩︎
Huang et al. Phospholipid metabolism in neurodegenerative diseases. Progress in Lipid Research. 2021. ↩︎
Zoeller et al. Phosphatidylserine biosynthesis in cultured neurons. Journal of Neurochemistry. 1991. ↩︎
Murphy et al. Apoptotic cell membrane phospholipids and neurodegeneration. Cell Death & Disease. 2019. ↩︎
Yang et al. Mitochondrial phospholipid metabolism in neurodegeneration. Biochimica et Biophysica Acta. 2020. ↩︎
Steenbergen et al. Phosphatidylserine and Alzheimer's disease. Biochemical and Biophysical Research Communications. 2005. ↩︎
Vandenberghe et al. Phosphatidylserine supplementation in cognitive decline. Alzheimer's & Dementia. 2023. ↩︎
Liu et al. Targeting phospholipid metabolism for neuroprotection. Pharmacological Research. 2022. ↩︎